Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal vs Oral Tranexamic Acid for Melasma
NCT07280234Phase 1Completed
- Sponsor
- Hayatabad Medical Complex
- Start
- Nov 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tranexamic acid in melasma (2 arms), sponsored by Hayatabad Medical Complex. Primary endpoint: modified Melasma Area and Severity Index at 8 weeks. Started Nov 2024; status: completed.
02
Drugs
tranexamic acid
03
Conditions
melasma
Beyond the preview
Go deeper on NCT07280234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07280234.